Human Serum With High Neutralizing Antibody Titers Against Both Zika and Dengue Virus Shows Delayed In Vitro Antibody-Dependent Enhancement of Dengue Virus Infection.
William G Valiant, Tahaniyat Lalani, Heather C Yun, Anjali Kunz, Timothy H Burgess, Joseph J Mattapallil
Author Information
William G Valiant: F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, Maryland.
Tahaniyat Lalani: Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Rockville, Maryland.
Heather C Yun: San Antonio Military Medical Center, San Antonio, Texas.
Anjali Kunz: Madigan Army Medical Center, Tacoma, Washington.
Timothy H Burgess: Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Rockville, Maryland.
Joseph J Mattapallil: F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, Maryland.
Zika virus infection in a dengue virus-naïve subject was associated with the induction of high levels of cross-reactive binding antibodies. These responses were, however, largely non-neutralizing and displayed a capacity to enhance dengue infection in vitro at significantly low dilution (1:10). In contrast, a subject who had high levels of neutralizing antibodies against both dengue and Zika viruses enhanced infection at a dilution of 1:10 000. These results suggest that high levels of dengue cross-neutralizing antibodies could potentially prevent the enhancement of dengue infection in Zika virus-convalescent individuals.
